AtriCure: Sustained Outperformance, Manageable Competition, and Undervalued Growth Support Buy Rating and $54 Target

Analyst Marie Thibault from BTIG reiterated a Buy rating on Atricure and keeping the price target at $54.00.

Marie Thibault has given his Buy rating due to a combination of factors, including AtriCure’s consistent operational outperformance and improved profitability outlook. The company delivered fourth-quarter revenue and full-year adjusted EBITDA above prior guidance, reiterated its 2026 revenue and EBITDA targets, and significantly raised its future earnings per share expectations, while also projecting sustained positive cash flow.

At the same time, Thibault views competitive concerns as already anticipated and manageable, noting AtriCure’s prior success defending share, its specialized ablation expertise, and strong customer relationships as durable competitive advantages. Solid growth in the appendage management franchise and a valuation that implies an undemanding sales multiple underpin her view that the shares remain undervalued relative to the company’s long-term growth and margin potential, supporting a Buy rating and a $54 price target.

In another report released today, Needham also reiterated a Buy rating on the stock with a $45.00 price target.

Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ATRC in relation to earlier this year.